UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 51

Sortiert nach

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

The lancet oncology, 2014-09, Vol.15 (10), p.1065-1075

2014

Link zum Volltext

Verfügbarkeit prüfen

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

The lancet oncology, 2016-10, Vol.17 (10), p.1426-1434

2016

Link zum Volltext

Verfügbarkeit prüfen

FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial

British journal of cancer, 2021-02, Vol.124 (3), p.587-594

2021

Link zum Volltext

Verfügbarkeit prüfen

Relation of early tumor shrinkage (ETS) observed in first‐line treatment to efficacy parameters of subsequent treatment in FIRE‐3 (AIOKRK0306)

International journal of cancer, 2017-04, Vol.140 (8), p.1918-1925

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase II Trial of Biweekly Infusional Fluorouracil, Folinic Acid, and Oxaliplatin in Patients With Advanced Gastric Cancer

Journal of clinical oncology, 2004-02, Vol.22 (4), p.658-663

2004

Link zum Volltext

Verfügbarkeit prüfen

Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3)

Journal of clinical oncology, 2013-06, Vol.31 (18_suppl), p.LBA3506-LBA3506

2013

Link zum Volltext

Verfügbarkeit prüfen

Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry

The European respiratory journal, 2023-02, Vol.61 (2), p.2201336

2023

Link zum Volltext

Verfügbarkeit prüfen

Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?

Clinical & translational oncology, 2024-05, Vol.26 (5), p.1268-1272

2024

Link zum Volltext

Verfügbarkeit prüfen

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

Blood, 2004-04, Vol.103 (8), p.2920-2924

2004

Link zum Volltext

Verfügbarkeit prüfen

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Clinical lymphoma, myeloma and leukemia, 2018-10, Vol.18 (10), p.e401-e419

2018

Link zum Volltext

Verfügbarkeit prüfen

Prognostic importance of primary tumor resection and synchronous metastasis on overall survival in metastatic colorectal cancer: Data from the FIRE-3 (AIO KRK-0306) study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4070-4070

2020

Link zum Volltext

Verfügbarkeit prüfen

Effect of patient age on efficacy of FOLFIRI plus cetuximab vs bevacizumab in 1st-line treatment of metastatic colorectal cancer: An analysis of FIRE-3 (AIO KRK 0306)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.3541-3541

2019

Link zum Volltext

Verfügbarkeit prüfen

Per protocol analysis and final OS update of the FIRE-3 (AIO KRK-0306) study comparing FOLFIRI plus cetuximab vs. FOLFIRI plus bevacizumab

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3508-3508

2018

Link zum Volltext

Verfügbarkeit prüfen

Primary tumor location and efficacy of second-line therapy after initial treatment with FOLFIRI in combination with cetuximab or bevacizumab in patients with metastatic colorectal cancer- FIRE-3 (AIOKRK0306)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3525-3525

2017

Link zum Volltext

Verfügbarkeit prüfen

Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

JTO clinical and research reports, 2024-04, Vol.5 (4), p.100626-100626, Article 100626

2024

Link zum Volltext

Verfügbarkeit prüfen

Time-course evaluation of survival and treatment in FIRE-3 trial (AIO KRK0306)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.3528-3528

2016

Link zum Volltext

Verfügbarkeit prüfen

Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases

Haematologica (Roma), 2002-01, Vol.87 (1), p.33

2002

Link zum Volltext

Verfügbarkeit prüfen

Treatment until progression: Data of the “on-treatment” population of the FIRE-3 (AIO KRK-0306) study

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3589-3589

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(51)

Sprache

Englisch
(51)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(30)
Life Sciences & Biomedicine
(30)
Science & Technology
(30)
Middle Aged
(21)
Male
(19)
Oncology
(19)
Female
(18)
Adult
(17)
Aged
(17)
Hematology
(14)
Biological And Medical Sciences
(13)
Medical Sciences
(13)
Interleukin-3 - Therapeutic Use
(10)
Pharmacology. Drug Treatments
(10)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Recombinant Proteins - Therapeutic Use
(7)
Antineoplastic Agents
(6)
Colorectal Cancer
(6)
Immunotherapy
(6)
Leucovorin - Administration & Dosage
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial

Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

Relation of early tumor shrinkage (ETS) observed in first‐line treatment to efficacy parameters of subsequent treatment in FIRE‐3 (AIOKRK0306)

Phase II Trial of Biweekly Infusional Fluorouracil, Folinic Acid, and Oxaliplatin in Patients With Advanced Gastric Cancer

Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3)

Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer

Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3

Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry

Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)

Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Prognostic importance of primary tumor resection and synchronous metastasis on overall survival in metastatic colorectal cancer: Data from the FIRE-3 (AIO KRK-0306) study

Effect of patient age on efficacy of FOLFIRI plus cetuximab vs bevacizumab in 1st-line treatment of metastatic colorectal cancer: An analysis of FIRE-3 (AIO KRK 0306)

Per protocol analysis and final OS update of the FIRE-3 (AIO KRK-0306) study comparing FOLFIRI plus cetuximab vs. FOLFIRI plus bevacizumab

Primary tumor location and efficacy of second-line therapy after initial treatment with FOLFIRI in combination with cetuximab or bevacizumab in patients with metastatic colorectal cancer- FIRE-3 (AIOKRK0306)

Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

Time-course evaluation of survival and treatment in FIRE-3 trial (AIO KRK0306)

Time-course evaluation of survival and treatment in FIRE-3 (AIO KRK0306, first-line therapy of KRAS wild-type metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab)

Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases

Treatment until progression: Data of the “on-treatment” population of the FIRE-3 (AIO KRK-0306) study

Baseline carcinoembryonic antigen (CEA) serum levels to predict bevacizumab-based treatment response in patients with KRAS exon wild-type metastatic colorectal cancer (mCRC) receiving 1st-line therapy with FOLFIRI plus cetuximab or bevacizumab (AIO KRK0306, FIRE3 trial)

Influence of adjuvant pretreatment on outcome of FIRE-3 (AIO KRK-0306): A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients

Suchergebnisse filtern